Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics

Current Opinion in Pharmacology

Volumn 32, Issue , 2017, Pages 77-84

  Siuda, Edward R ^a   Carr, Richard ^a   Rominger, David H ^a   Violin, Jonathan D ^a  

^a TREVENA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; BETA ARRESTIN 2; BUPRENORPHINE; FENTANYL; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GUANINE NUCLEOTIDE BINDING PROTEIN; MITRAGYNINE PSEUDOINDOXYL; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; OLICERIDINE; PLACEBO; PZM 21; UNCLASSIFIED DRUG; LIGAND; NARCOTIC ANALGESIC AGENT;

ABDOMINOPLASTY; ANALGESIC ACTIVITY; ANTINOCICEPTION; BUNIONECTOMY; CONDITIONED PLACE PREFERENCE TEST; CONSTIPATION; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG STRUCTURE; DRUG TOLERANCE; HOT PLATE TEST; HUMAN; LOADING DRUG DOSE; NAUSEA; NAUSEA AND VOMITING; NOCICEPTIVE PAIN; NONHUMAN; PATIENT CONTROLLED ANALGESIA; PERIAQUEDUCTAL GRAY MATTER; POSTOPERATIVE ILEUS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RESPIRATION DEPRESSION; REVIEW; REWARD; TACHYPHYLAXIS; TAIL FLICK TEST; VOMITING; AGONISTS; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PAIN; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANALGESICS, OPIOID; ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MORPHINE; PAIN; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 85002189064     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.11.007     Document Type: Review

References (75)

1. 1 Ramoutsaki, I.A., Askitopoulou, H., Konsolaki, E., Pain relief and sedation in Roman Byzantine texts: Mandragoras officinarum, Hyoscyamos niger and Atropa belladonna. Int Congr Ser 1242 (2002), 43–50.
2. 2 Santoro, D., Bellinghieri, G., Savica, V., Development of the concept of pain in history. J Nephrol 24:Suppl. 17 (2011), S133–S136.
3. 3 Medicines, W.M.L.O.E., The selection and use of essential medicines. World Health Organ Tech Rep Ser, 2015, vii–xv 1–546.
4. 4 Pert, C.B., Snyder, S.H., Opiate receptor: demonstration in nervous tissue. Science 179 (1973), 1011–1014.
5. 5 Martin, M., et al. Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. Eur J Neurosci 17 (2003), 701–708.
6. 6 Matthes, H.W., et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383 (1996), 819–823.
7. 7 Janssen, P.A., Niemegeers, C.J., Dony, J.G., The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneimittelforschung 13 (1963), 502–507.
8. 8 Heel, R.C., et al. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 17 (1979), 81–110.
9. 9 Osterloh, G., et al. General pharmacological studies on tramadol, a potent analgetic agent (author's transl). Arzneimittelforschung 28 (1978), 135–151.
10. 10 Raffa, R.B., Martinez, R.P., Connelly, C.D., G-protein antisense oligodeoxyribonucleotides and mu-opioid supraspinal antinociception. Eur J Pharmacol 258 (1994), R5–R7.
11. 11 Sanchez-Blazquez, P., Gomez-Serranillos, P., Garzon, J., Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 54 (2001), 229–235.
12. 12 Marker, C.L., et al. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. J Neurosci 25 (2005), 3551–3559.
13. 13 Bourinet, E., et al. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci U S A 93 (1996), 1486–1491.
14. 14 Bohn, L.M., et al. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408 (2000), 720–723.
15. 15 Raehal, K.M., Walker, J.K., Bohn, L.M., Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314 (2005), 1195–1201.
16. 16 Groer, C.E., et al. Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem 286 (2011), 31731–31741.
17. 17 Bohn, L.M., et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286 (1999), 2495–2498.
18. 18 Shenoy, S.K., et al. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294 (2001), 1307–1313.
19. 19 Shenoy, S.K., et al. Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2. Proc Natl Acad Sci U S A 106 (2009), 6650–6655.
20. 20 Zheng, M., et al. Beta-arrestin2 plays permissive roles in the inhibitory activities of RGS9-2 on G protein-coupled receptors by maintaining RGS9-2 in the open conformation. Mol Cell Biol 31 (2011), 4887–4901.
21. 21 Shenoy, S.K., et al. Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281 (2006), 1261–1273.
22. 22 Luttrell, L.M., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283 (1999), 655–661.
23. 23 Guo, C., Whitmarsh, A.J., The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus. J Biol Chem 283 (2008), 15903–15911.
24. 24 Bruchas, M.R., et al. Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281 (2006), 18081–18089.
25. 25 Oakley, R.H., et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275 (2000), 17201–17210.
26. 26 Bohn, L.M., et al. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66 (2004), 106–112.
27. 27 Kenakin, T., Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336 (2011), 296–302.
28. 28• Kenakin, T., Christopoulos, A., Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12 (2013), 205–216 This review discusses methods of calculating ligand bias and summarizes many of the key challenges that can hinder the discovery of biased ligands.
29. 29 Wisler, J.W., et al. Recent developments in biased agonism. Curr Opin Cell Biol 27 (2014), 18–24.
30. 30 Gentry, P.R., Sexton, P.M., Christopoulos, A., Novel allosteric modulators of G protein-coupled receptors. J Biol Chem 290 (2015), 19478–19488.
31. 31 Violin, J.D., Lefkowitz, R.J., Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28 (2007), 416–422.
32. 32 Zocher, M., et al. Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human beta2 adrenergic receptor. Structure 20 (2012), 1391–1402.
33. 33 Gaieb, Z., Lo, D.D., Morikis, D., Molecular mechanism of biased ligand conformational changes in CC chemokine receptor 7. J Chem Inf Model, 2016.
34. 34• Manglik, A., et al. Structural insights into the dynamic process of beta2-adrenergic receptor signaling. Cell 161 (2015), 1101–1111 Utilizing the β2-adrenergic receptor, the authors demonstrate that in the presence of ligand, there is receptor conformational heterogeneity and hence inactive, intermediate, and active states may coexist. This may explain how biased ligands engage differential signaling pathways.
35. 19F-NMR. Science 335 (2012), 1106–1110.
36. 36 Black, J.W., Leff, P., Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220 (1983), 141–162.
37. 37 Ehlert, F.J., On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn Schmiedebergs Arch Pharmacol 377 (2008), 549–577.
38. 38 Thompson, G.L., et al. Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. Biochem Pharmacol 113 (2016), 70–87.
39. 39 Gesty-Palmer, D., et al. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med, 1, 2009, 1ra1.
40. 40 Wisler, J.W., et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 104 (2007), 16657–16662.
41. 41 Kim, I.M., et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 105 (2008), 14555–14560.
42. 42 Violin, J.D., et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335 (2010), 572–579.
43. 2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice. Neuropsychopharmacology 41 (2016), 704–715 This manuscript explores the contribution of biased signaling at dopamine 2 receptors in schizophrenia. Utilizing arrestin biased ligands, the authors show enhanced efficacy at treating symptoms of schizophrenia in mice with reduced side effects.
44. 44 Groer, C.E., et al. An opioid agonist that does not induce mu-opioid receptor — arrestin interactions or receptor internalization. Mol Pharmacol 71 (2007), 549–557.
45. 45 Lamb, K., et al. Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121 (2012), 181–188.
46. 46 Chen, X.T., et al. Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem 56 (2013), 8019–8031.
47. 47•• DeWire, S.M., et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344 (2013), 708–717 This manuscript introduces the G protein-biased MOR agonist, TRV130. Utilizing various in vitro and in vivo techniques, the authors demonstrate that TRV130 possesses different pharmacological properties and exhibits improved analgesia, less constipation and less respiratory depression as compared to traditional MOR agonists.
48. 48•• Manglik, A., et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature, 2016, 1–6 Utilizing the MOR crystal structure, the authors use structure based docking and optimization to discover a new chemotype of G protein biased ligands, PZM21. In addition to analgesia, PZM21 results in less constipation and less respiratory depression and does not induce a conditioned place preference response. It also introduces the theory that opioid agonists may also differentially ameliorate the reflexive and affective components of pain.
49. 49 Bohn, L.M., et al. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 23 (2003), 10265–10273.
50. 50•• Varadi, A., et al. Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism which do not recruit beta-arrestin-2. J Med Chem, 2016 Here, Varadi et al. look to natural products and describe a MOR agonist/DOR antagonist that does not recruit arrestin. Mitragynine pseudoindoxyl, a synthetically derived metabolite of mitragynine from the South Asian plant kratom, developed slower analgesic tolerance, limited symptoms of physical dependence, reduced respiratory depression, reduced constipation, and did not induce conditioned place preference or aversion when compared to morphine.
51. 51 Zadina, J.E., et al. Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine. Neuropharmacology 105 (2016), 215–227.
52. 52 Li, Y., et al. Improvement of morphine-mediated analgesia by inhibition of beta-arrestin 2 expression in mice periaqueductal gray matter. Int J Mol Sci 10 (2009), 954–963.
53. 53 Jiang, B., et al. Decreased morphine analgesia in rat overexpressing beta-arrestin 2 at periaqueductal gray. Neurosci Lett 400 (2006), 150–153.
54. 54 Lalley, P.M., et al. CrossTalk opposing view: the pre-Bötzinger complex is not essential for respiratory depression following systemic administration of opioid analgesics. J Physiol 592:Pt 6 (2014), 1163–1166.
55. 55 Montandon, G., Horner, R., CrossTalk proposal: the preBötzinger complex is essential for the respiratory depression following systemic administration of opioid analgesics. J Physiol 592:Pt 6 (2014), 1159–1162.
56. 56 Wang, Z.Z., et al. The co-existence of biogenic amines and neuropeptides in the type I cells of the cat carotid body. Neuroscience 47 (1992), 473–480.
57. 57 Wharton, J., et al. Enkephalin-, VIP- and substance P-like immunoreactivity in the carotid body. Nature 284 (1980), 269–271.
58. 58 Pattinson, K.T.S., Opioids and the control of respiration. Br J Anaesth 100 (2008), 747–758.
59. 59 Nagi, K., Pineyro, G., Kir3 channel signaling complexes: focus on opioid receptor signaling. Front Cell Neurosci, 8, 2014.
60. 60 Montandon, G., et al. G-protein-gated inwardly rectifying potassium channels modulate respiratory depression by opioids. Anesthesiology 124 (2016), 641–650.
61. 61 Akbarali, H.I., Inkisar, A., Dewey, W.L., Site and mechanism of morphine tolerance in the gastrointestinal tract. Neurogastroenterol Motil 26 (2014), 1361–1367.
62. 62 Wood, J.D., Galligan, J.J., Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16:Suppl. 2 (2004), 17–28.
63. 63 Sugahara, S., et al. Effects of intrathecal and intraperitoneal morphine on gastrointestinal motility in the rat. Eur J Anaesthesiol 9 (1992), 341–346.
64. 64 Nelson, A.D., Camilleri, M., Opioid-induced constipation: advances and clinical guidance. Ther Adv Chronic Dis 7 (2016), 121–134.
65. 65 Mori, T., et al. Mechanisms that underlie mu-opioid receptor agonist-induced constipation: differential involvement of mu-opioid receptor sites and responsible regions. J Pharmacol Exp Ther 347 (2013), 91–99.
66. 66 Kang, M., et al. The role of beta-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J Pharmacol Exp Ther 340 (2012), 567–576.
67. 67 Galligan, J.J., Akbarali, H.I., Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl 2 (2014), 17–21.
68. 68 Bohn, L.M., Belcheva, M.M., Coscia, C.J., Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells. J Neurochem 74 (2000), 574–581.
69. 69 Gan, T.J., et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 118 (2014), 85–113.
70. 70 Ronen, M., et al. Smart respiratory monitoring: clinical development and validation of the IPI (Integrated Pulmonary Index) algorithm. J Clin Monit Comput, 2016.
71. 71 Overdyk, F.J., et al. Association of opioids and sedatives with increased risk of in-hospital cardiopulmonary arrest from an administrative database. PLOS ONE, 11, 2016, e0150214.
72. 72 Soergel, D.G., et al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol 54 (2014), 351–357.
73. 73• Soergel, D.G., et al. Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155 (2014), 1829–1835 Here the authors demonstrate the activity of the G protein-biased μ opioid receptor ligand, oliceridine (TRV130), in healthy humans. Oliceridine was well tolerated and produced greater analgesia than morphine with less effect on respiratory drive, less vomiting, and less severe nausea.
74. 74 Singla, N., et al. A randomized, placebo-and active-controlled phase 2b abdominoplasty study investigating oliceridine(TRV130), a novel μ receptor G protein pathway selective (μ-GPS) modulator. American Society of Regional Anesthesia 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting, New Orleans, LA, 2016.
75. 75 BreakthroughTherapies, www.focr.org/breakthrough-therapies.